Previous Close | 125.85 |
Open | 127.24 |
Bid | 125.03 x 800 |
Ask | 125.59 x 800 |
Day's Range | 125.05 - 128.70 |
52 Week Range | 99.14 - 134.63 |
Volume | |
Avg. Volume | 8,233,711 |
Market Cap | 317.26B |
Beta (5Y Monthly) | 0.39 |
PE Ratio (TTM) | 139.18 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.08 (2.46%) |
Ex-Dividend Date | Sept 16, 2024 |
1y Target Est | N/A |
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports second-quarter 2024 earnings.
Key Insights Significantly high institutional ownership implies Merck's stock price is sensitive to their trading...
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.